Accuray Incorporated  (ARAY)
Other Ticker:  
Price: $2.6600 $0.01 0.377%
Day's High: $2.735 Week Perf: -3.27 %
Day's Low: $ 2.65 30 Day Perf: 1.14 %
Volume (M): 268 52 Wk High: $ 4.30
Volume (M$): $ 712 52 Wk Avg: $2.99
Open: $2.69 52 Wk Low: $1.85

 Market Capitalization (Millions $) 257
 Shares Outstanding (Millions) 97
 Employees 1,000
 Revenues (TTM) (Millions $) 454
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 14

Accuray Incorporated
Accuray Incorporated is a global provider of innovative precision radiation medicine solutions. The company was founded in 1990 and is headquartered in Sunnyvale, California, USA. The company's mission is to develop and deliver advanced radiation therapies that help people live longer, healthier lives.

Accuray's flagship product is the CyberKnife' System, which is the world's first and only robotic radiotherapy system designed to treat tumors anywhere in the body with sub-millimetric accuracy. The CyberKnife System uses advanced image guidance technology to track and adjust for the patient's breathing and movement, allowing for precise radiation delivery to the tumor while sparing surrounding healthy tissue.

The company also offers the TomoTherapy' System, a comprehensive radiation therapy system that combines precise treatment delivery with integrated CT imaging to effectively target tumors while minimizing exposure to healthy tissue. The TomoTherapy System is used for the treatment of a wide range of cancers, including prostate, breast, lung, head and neck, and brain tumors.

In addition, Accuray provides quality assurance and service management solutions for radiation therapy clinics through its AQUA' software platform. AQUA provides real-time monitoring and reporting of treatment machine performance and maintenance to ensure that treatments are delivered accurately and safely.

Accuray has a global footprint, with offices in the Americas, Europe, and Asia. The company has a strong focus on research and development, and invests heavily in advanced technologies to improve cancer treatment outcomes. Accuray's products and solutions have been used to treat over a million patients worldwide.

Overall, Accuray's precision radiation medicine solutions offer patients better treatment options, improved outcomes, and a higher quality of life. The company's dedication to innovation and patient-centered care has positioned it as a leader in the radiation therapy industry.

   Company Address: 1240 Deming Way Madison 53717 WI
   Company Phone Number: 824-2800   Stock Exchange / Ticker: NASDAQ ARAY
   ARAY is expected to report next financial results on February 01, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Pavmed Inc

Pavmed Inc has failed to break-even despite the epic Surge in revenue in the financial time-frame ending September 30 2023

Pavmed Inc announced very solid Revenue improvement of 1103.947 % year on year to $0.92 million in the third quarter of 2023 earnings season, but lost money at $-0.16. Medical Equipment and Supplies company's business grew faster in contrast to the the revenue at nearly all of the Medical Equipment and Supplies industry contemporaries, in the third quarter of 2023 the two third entities in Medical Equipment and Supplies industries saw an average business improvement of 5.23% from the comparable reporting period a year ago.

Beyond Air Inc

The Medical Equipment and Supplies company announced Revenue of $0.239 million, in the July to September 30 2023

XAIR proclaimed $0.239 million, in Revenue in the financial period ending September 30 2023.

Sintx Technologies Inc

The company disclosed a quick revenue increase , in the financial span closing Sep 30 2023

For the third quarter of 2023 earnings season Sintx Technologies Inc increased a deficit per share of $-0.81 per share compare to $-0.11 a year prior and surged deficit from $-0.78 per share from the preceding reporting period. The revenue rose strongly by 59.155 % to $0.68 million from $0.43 million in the comparable reporting period a year prior and sequentially revenue surged by 33.465 % from $0.51 million. Medical Equipment and Supplies company's revenue, surge in the third quarter of 2023 compares advantageously to its Medical Equipment and Supplies sector contemporaries, which experienced all in all 5.23 % top-line elevation during the matching time yet.

Patterson Companies Inc

PDCO Reports Modest Revenue Rise, but Faces Steep Decline in Income in Latest Fiscal Period

Patterson Companies Inc, a leading player in the Medical Equipment and Supplies sector, recently released its financial results for the most recent fiscal period. Despite a modest revenue elevation of 1.588%, the company experienced a significant income contraction of -23.64% compared to the same quarter a year ago. This downturn in income can be attributed to various factors within the industry.
During the period in question, Patterson Companies Inc generated $1.65 billion in revenue and earnings per share (EPS) of $0.42. While these figures may seem promising, considering the growth in revenue and EPS, it is important to note that the company's performance lagged behind its sector peers. The Medical Equipment and Supplies sector witnessed a 5.93% rise in business during the second quarter of 2023, indicating that Patterson Companies Inc did not keep up with the industry's growth trajectory.

Embecta Corp

Embecta Corp Faces Significant Decline in Revenue During Fourth Quarter of 2023

Financial News Report:
Embecta Corp (NASDAQ: EMBC), a global diabetes care company, has reported a significant decline in income and profit for the July to September 2023 period. The company's income fell sharply by -92.65% to $0.10 per share compared to $1.42 per share in the same period last year. Additionally, profit plummeted by -59.89% from $0.26 per share in the prior quarter.
The revenue of Embecta Corp also went down sharply by -50.062% to $281.60 million from $563.90 million in the corresponding quarter a year prior. This is a sequential decrease of -1.366% from $285.50 million. In comparison, the rest of the Medical Equipment and Supplies sector posted a top-line growth in the fourth quarter of 2023.


Accuray Incorporated's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com